Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. The oral EGFR inhibitor sunvozertinib (Zegfrovy) is ...

AstraZeneca has begun selling a Chinese-developed lung cancer drug in the U.S. that some American patients had been flying to ...

Bengaluru: AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment ...

However, the study found that a third dose of the Pfizer vaccine, and mixing Pfizer and AstraZeneca preventives may protect ...

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...

The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc’s AZN Ultomiris ...

AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...

AstraZeneca’s Zegfrovy demonstrated a 46% overall response rate in a trial supporting its accelerated FDA approval, as the ...

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval in primary immunoglobulin A nephropat ...

The FDA grants Ultomiris accelerated approval to reduce proteinuria in adults with IgA nephropathy at risk of progression.